BC Week In Review | Feb 16, 2017
Clinical News

Kevetrin: Ph IIa started

Cellceutix began an open-label, U.S. Phase IIa trial to evaluate 250 and 350 mg/m 2 IV Kevetrin thrice weekly for 3 weeks in about 10 patients. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass.  Product: Kevetrin thioureidobutyronitrile  Business:...
BC Week In Review | Aug 22, 2016
Clinical News

Kevetrin thioureidobutyronitrile: Additional Phase I data

An open-label, dose-escalation, U.S. Phase I trial in about 48 patients with advanced solid tumors showed that once-weekly 10-750 mg/m 2 IV Kevetrin given for the first 3 weeks of each 4-week cycle met the...
BC Week In Review | Nov 23, 2015
Clinical News

Kevetrin thioureidobutyronitrile: Completed Phase I enrollment

Cellceutix completed enrollment of >40 patients in an open-label, dose-escalation, U.S. Phase I trial evaluating IV Kevetrin given once weekly for the first 3 weeks of a 4-week cycle. Next half, the company plans to...
BC Week In Review | Aug 24, 2015
Clinical News

Thioureidobutyronitrile: Interim Phase I data

Interim data from 1 patient with stage IV thymoma in his eleventh month of treatment in an open-label, dose-escalation, U.S. Phase I trial showed that once-weekly IV Kevetrin for the first 3 weeks of a...
BC Innovations | Jun 20, 2013
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammatory disease Leukotriene B4 (LTB4); complement 5 (C5) In vitro and mouse studies suggest inhibitors of both C5 and LTB4 could help treat inflammatory diseases....
BC Week In Review | Mar 18, 2013
Clinical News

Cellceutix preclinical data

In nude mice implanted subcutaneously with human retinoblastoma cells, Kevetrin significantly reduced tumor volume by >50% vs. controls. Cellceutix said Kevetrin also significantly improved clarity of the eye vs. controls, but did not disclose details....
BC Week In Review | Oct 29, 2012
Clinical News

Kevetrin thioureidobutyronitrile: Phase I started

Cellceutix began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV Kevetrin given once weekly for the first 3 weeks of a 4-week cycle in about 40 patients with advanced solid tumors. In March,...
BC Week In Review | Jul 30, 2012
Clinical News

Kevetrin: Phase I start

In August, Cellceutix will begin a U.S. Phase I trial to evaluate Kevetrin. In March, Cellceutix partnered with Beth Israel Deaconess Medical Center (Boston, Mass.) to research Kevetrin to treat melanoma and renal cell carcinoma...
BC Week In Review | Mar 26, 2012
Company News

Cellceutix, Beth Israel Deaconess deal

Cellceutix and the center partnered to research Cellceutix's Kevetrin to treat melanoma and renal cell carcinoma (RCC). Kevetrin is a small molecule protein kinase B (PKB; PKBA; AKT; AKT1) inhibitor that also acts as an...
BC Week In Review | Dec 19, 2011
Clinical News

Kevetrin regulatory update

Cellceutix said FDA reviewed an IND for Kevetrin and advised it that the batch formulation of the cancer product needs to be redone after operations were ceased at contract manufacturer Formatech Inc. (Andover, Mass.). Cellceutix...
Items per page:
1 - 10 of 22